{"article_title": "Gilead: Buy the Dip", "article_keywords": ["gilead", "buy", "dip"], "article_url": "http://www.barrons.com/articles/gilead-buy-the-dip-1414606420", "article_text": "", "article_metadata": {"article.template": "snippet", "article.created": "2014-10-29T18:13:00.000Z", "lifp_basePath": "https://id.barrons.com/access", "page.region": "na,us", "page.content.type": "Article", "twitter": {"image": {"src": "https://si.wsj.net/public/resources/images/ON-BG712_Gilead_G_20141029125523.jpg", "alt": "Gilead: Buy the Dip", "identifier": "https://si.wsj.net/public/resources/images/ON-BG712_Gilead_D_20141029125523.jpg"}, "description": "Shares are down on mixed quarterly results. However, the stock could well surge to $170, given high hopes for the hepatitis C drug Harvoni.", "card": "summary_large_image", "title": "Gilead: Buy the Dip"}, "page.site.product": "WSJ", "keywords": "performance,earnings projections,analyst comments,recommendations,corporate,industrial news,political,general news,health,hepatitis,medical conditions,biotechnology,pharmaceuticals,health care,life sciences,biopharmaceuticals,drugs,medication", "news_keywords": "performance,earnings projections,analyst comments,recommendations,corporate,industrial news,political,general news,health,hepatitis", "article.headline": "Gilead: Buy the Dip", "description": "Shares are down on mixed quarterly results. However, the stock could well surge to $170, given high hopes for the hepatitis C drug Harvoni.", "apple-itunes-app": "app-id=409882593,app-argument=barrons://launch?articleid=SB52124669936348073286504580244634211529968&headline=Gilead%3A%20Buy%20the%20Dip&weburl=http://www.barrons.com/articles/SB52124669936348073286504580244634211529968", "user.type": "nonsubscriber", "article.page": "Weekday", "article.section": "Home", "article.summary": "Shares are down on mixed quarterly results. However, the stock could well surge to $170, given high hopes for the hepatitis C drug Harvoni.", "page.site": "barrons", "testkeys": "A", "article.published": "2014-10-29T04:01:00.000Z", "dj.asn": "i-4edb", "robots": "noarchive,noodp", "fb": {"app_id": 143538339355}, "article": {"internal_link_count": 2, "embed_count": 1, "word_count": 572}, "viewport": "width=device-width, user-scalable=yes, target-densitydpi=160", "page.section": "Article", "language": "en-US", "og": {"description": "Shares are down on mixed quarterly results. However, the stock could well surge to $170, given high hopes for the hepatitis C drug Harvoni.", "title": "Gilead: Buy the Dip", "url": "http://www.barrons.com/articles/gilead-buy-the-dip-1414606420", "image": {"width": 553, "identifier": "https://si.wsj.net/public/resources/images/ON-BG712_Gilead_G_20141029125523.jpg", "height": 369}, "locale": "en_US", "type": "article"}, "author": "Teresa Rivas", "article.access": "paid", "page.content.source": "Barron's Online", "article.origheadline": "Gilead: Buy the Dip", "article.type": "Barron's Take", "article.id": "SB52124669936348073286504580244634211529968", "user.exp": "default", "article.updated": "2014-10-29T04:01:00.000Z"}, "article_summary": ""}